Peritoneal and meningeal relapse from lung adenocarcinoma after a response to gefitinib: A case report

Kurishima,Koichi; Miyazaki,Kunihiko; Tamura,Tomohiro; Ohara,Gen; Kagohashi,Katsunori; Kawaguchi,Mio; Satoh,Hiroaki

doi:10.3892/mco.2013.122

Peritoneal and meningeal relapse from lung adenocarcinoma after a response to gefitinib: A case report

Authors:
- Koichi Kurishima
- Kunihiko Miyazaki
- Tomohiro Tamura
- Gen Ohara
- Katsunori Kagohashi
- Mio Kawaguchi
- Hiroaki Satoh
View Affiliations

Affiliations: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310-0015, Japan
Published online on: May 16, 2013 https://doi.org/10.3892/mco.2013.122
Pages: 785-787

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis of carcinomatous peritonitis and meningitis is poor since ascites and focal neurological dysfunctions usually do not improve despite the available treatment options for this devastating disease. This is a case report of peritoneal and meningeal relapse from lung adenocarcinoma following a response to gefitinib. A 72‑year‑old woman was diagnosed with adenocarcinoma in the upper lobe of the left lung, accompanied by a massive carcinomatous pleural effusion. Following a cisplatin‑based chemotherapy, gefitinib was initiated, achieving satisfactory disease control. At 8 months after gefitinib initiation, the patient developed abdominal distension, gait disturbance and visual disorder of the right eye. Adenocarcinoma cells were detected in the ascitic and pleural fluids. The findings of this case report suggest that clinicians should remain vigilant for this type of metastasis, although it is rarely encountered.

View Figures

View References

1.	Satoh H, Ishikawa H, Yamashita YT, et al: Peritoneal carcinomatosis in lung cancer patients. Oncol Rep. 8:1305–1307. 2001.PubMed/NCBI
2.	Kim MK, Lee KH, Lee JK, et al: Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer. 50:265–269. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Yi HG, Kim HJ, Kim YJ, et al: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer. 65:80–84. 2009. View Article : Google Scholar
4.	Langer C and Soria JC: The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 11:82–90. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Katayama T, Shimizu J, Suda K, et al: Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 4:1415–1419. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Ruppert AM, Beau-Faller M, Neuville A, et al: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J. 33:436–440. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Togashi Y, Masago K, Fukudo M, et al: Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 5:950–955. 2010.PubMed/NCBI
8.	Masuda T, Hattori N, Hamada A, et al: Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol. 67:1465–1469. 2011. View Article : Google Scholar
9.	Ano S, Satoh H, Nakazawa K, et al: Malignant meningitis secondary to lung adenocarcinoma: an unusual relapse. Intern Med. 46:1749–1751. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Jiménez Mateos A, Cabrera Naranjo F, González Hernández A, et al: Neoplastic meningitis. Review of a clinical series. Neurologia. 26:227–232. 2011.
11.	Grossman SA and Krabak MJ: Leptomeningeal carcinomatosis. Cancer Treat Rev. 25:103–119. 1999. View Article : Google Scholar
12.	Wasserstrom WR, Glass JP and Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 49:759–772. 1982. View Article : Google Scholar : PubMed/NCBI
13.	Strik H and Prömmel P: Diagnosis and individualized therapy of neoplastic meningitis. Expert Rev Anticancer Ther. 10:1137–1148. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Omuro AM, Kris MG, Miller VA, et al: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 103:2344–2248. 2005. View Article : Google Scholar : PubMed/NCBI
15.	McNeill PM, Wagman LD and Neifeld JP: Small bowel metastases from primary carcinoma of the lung. Cancer. 59:1486–1489. 1987. View Article : Google Scholar : PubMed/NCBI
16.	Abrams HL, Spiro R and Goldstein N: Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 3:74–85. 1950. View Article : Google Scholar : PubMed/NCBI
17.	Warren S and Gates O: Lung cancer and metastasis. Arch Pathol. 78:467–473. 1964.PubMed/NCBI
18.	Su HT, Tsai CM and Perng RP: Peritoneal carcinomatosis in lung cancer. Respirology. 13:465–467. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Nakata H, Tuji T and Ohsaki Y: A case of peritonitis carcinomatosa of pulmonary adenocarcinoma in which gefitinib was effective. Cancer Chemother. 31:87–89. 2004.(In Japanese).